NCT04155515View on ClinicalTrials.gov

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

370

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

August 11, 2020

Study Completion Date

August 11, 2020

Conditions

Chronic Hepatics C Virus (HCV) Genotype 1Non-CirrhoticCirrhosisTreatment naïve

Interventions

DRUG

TG-2349

TG-2349 400mg

DRUG

DAG181

DAG181 200mg

DRUG

Ribavirin

Ribavirin 1000mg/1200mg

Trial Locations (1)

Unknown

Beijing Tsinghua Changgung Hospital, Beijing

All Listed Sponsors

lead

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT04155515 - A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients | Biotech Hunter | Biotech Hunter